Coherus Oncology (CHRS) Research & Development (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Research & Development data on file, last reported at $21.5 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 11.55% year-over-year to $21.5 million; the trailing twelve-month figure through Mar 2026 stood at $106.1 million (up 20.86% YoY), and the FY2025 full-year result was $108.9 million, up 18.57% from the prior year.
• Research & Development declined to $21.5 million in Q1 2026, from $31.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $82.9 million in Q1 2022 to a low of $20.6 million in Q2 2024.
• A 5-year average of $31.2 million and a median of $26.4 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 621.02% in 2022 and sank 58.81% in 2023, its largest moves.
• Tracing CHRS's Research & Development over 5 years: stood at $29.0 million in 2022, then fell by 9.14% to $26.4 million in 2023, then retreated by 21.27% to $20.8 million in 2024, then jumped by 49.21% to $31.0 million in 2025, then slumped by 30.45% to $21.5 million in 2026.
• Business Quant data shows CHRS's Research & Development at $21.5 million in Q1 2026, $31.0 million in Q4 2025, and $27.3 million in Q3 2025.